Even if inodilators are often used in cardiac surgery and more than 1 million cardiac surgery procedures are performed worldwide every year, no large multicentre randomised trial exists to document differences in mortality when using different inodilators in cardiac surgery. Most randomised controlled trials performed on inodilators in cardiac surgery are small and, even if mortality data is often reported, it is difficult to determine which is the best agent in terms of survival. Furthermore, most published trials compare levosimendan vs placebo and milrinone vs placebo while it would be desirable to have direct comparison between inodilators. Preliminary evidence derived from meta-analyses of randomised trials, suggests that levosimendan reduces mortality in cardiac surgery but data are not updated, are not focused on inodilators and no attempt to grade the different inodilators was performed so far. The inclusion of indirect comparisons might in fact add pieces of information in a setting with scarce direct comparisons.
Our research question was to investigate which inodilator is associated with the lowest mortality after cardiac surgery. To achieve this aim we first identified and merged all randomised trials ever published on any inodilator drug (levosimendan, enoximone, milrinone and dobutamine) in adult cardiac surgery that reported mortality data. We therefore performed a Bayesian network meta-analysis of randomised trials to grade all the inodilators in order to allow physicians to optimize cost-effectiveness analyses in their centres. A network meta-analysis is a statistical technique for comparison of different treatments that were never properly studied through adequately powered randomised controlled trials, but that can be compared through a third common comparator. 6 7 On the basis of statistical inference, it is possible to identify the superior treatment, reaching, through indirect comparison, reliable conclusions otherwise hard or impossible to achieve.
Methods
To understand whether inodilators might influence patients' survival after adult cardiac surgery we carried out a Bayesian network meta-analysis to compare the effect on mortality of levosimendan, enoximone, milrinone and dobutamine. A Bayesian network meta-analysis is a valid method of indirectly comparing drugs that did not undergo sufficient head-to-head comparison in the original clinical trials. 6 7 Search strategy and study selection 
Study selection
References obtained from database, literature searches with cross-check of references and experts were first independently examined on a title/abstract level by two investigators and then, if potentially relevant, retrieved as complete articles.
No language restriction was enforced and non-English articles were translated and included in the analyses. The following inclusion criteria were used for potentially relevant studies: random allocation to treatment with at least one group receiving dobutamine, enoximone, levosimendan, or milrinone and at least another group receiving dobutamine, enoximone, levosimendan, milrinone or placebo (since patients undergoing cardiac surgery often require inotropic agents to survive, it is often impossible to compare a drug to a placebo in this context; most authors of the included trials treated their patients with the best available standard treatment and then added or not the study drug; as a consequence, placebo in this meta-analysis was considered as 'placebo on top of standard treatment' or as 'standard treatment alone'). Studies had to be performed in an adult cardiac surgery setting with no restriction in dose and time of administration. The exclusion criteria were duplicate publications (in this case the article reporting the longest follow-up was abstracted), nonhuman experimental studies, and lack of outcome (survival) data. Two investigators independently assessed articles for inclusion criteria and selected studies for the final analysis, with divergences finally resolved by consensus.
Data abstraction and study characteristics
Baseline, procedural and outcome data were independently abstracted by two trained investigators, with divergences resolved by consensus ( Table 1 ). The following data were extracted and collected in a spreadsheet file: author identification, year and journal of publication, study comparators, treatment sample sizes, type of surgery, longest follow-up and mortality. The endpoints of the present review was to identify differences in mortality at the longest follow-up available between each inodilator agent and to identify if one or more were superior or inferior in terms of survival, using standard meta-analyses and Bayesian network meta-analyses. When a study had missing or incomplete data on survival we contacted all authors by e-mail, letter or both.
Internal validity and risk of bias assessment
The internal validity of each trial included in this review was critically evaluated for bias according to The Cochrane Collaboration methods, i.e. judging the risk for selection, performance, attrition, detection and reporting biases. We evaluated the potential source of bias by applying a rating of 'Yes', 'No' or 'Unclear' to denote whether adequate measures were taken to protect against each potential source of bias in each study. The overall risk of bias was expressed as low, moderate or high. Publication bias was assessed by visually inspecting funnel plots.
Statistical analysis
For each trial, the proportion of deaths were analysed and expressed as the logarithm of odds ratio (OR) and of its standard error (SE). Whenever possible we used results from intention-to-treat population.
Each arm of the trials was classified according to its primary treatment strategy. The primary treatment strategies of interest in Effect of inodilatory agents on mortality Continued this Bayesian network meta-analysis were 1) placebo, 2) levosimendan, 3) enoximone, 4) milrinone, 5) dobutamine. The pairwise association between each treatment (also called 'direct estimate') was delineated by a graphical representation of the network. In the diagram each node represents a single anaesthetic agent and each edge connects treatments that have been directly compared in one or more RCTs. We performed pairwise meta-analyses to look at the direct comparisons. In the standard meta-analyses, a magnitude of heterogeneity between-studies was represented by the degree of inconsistency (I 2 ), while uncertainty over whether apparent heterogeneity due to the effects of chance (random error) was expressed using p-value from Cochrane Q statistic. The presence of effect-modifiers due heterogeneity was considered acceptable with one chi-square P-value .0.10. Mortality data from individual studies were analysed to compute pooled OR with pertinent 95% confidence intervals (CI) by means of the inverse of variance method with fixed effect model in case of low statistical inconsistency (I 2 ≤25%) or by means of DerSimonian-Laird method with random effect model (which better accommodates clinical and statistical variations) in case of moderate or high statistical inconsistency (I 2 .25%). The number need to treat (NNT) was computed for the significant associations. The robustness of the standard meta-analysis was assessed by sequentially removing each study from the overall dataset and reanalysing the remaining datasets. The Bayesian network analysis was carried out modeling the outcome mortality with the Bayesian hierarchical model (binomial model with logit link function) using Markov chain Monte Carlo (MCMC) approach. Pooled ORs comparing different inodilators were estimated from the mean of the posterior distribution obtained with Bayesian analysis. The indirect estimate was calculated by means of consistency equation Log(OR) 23 ¼Log(OR) 13 -Log(OR) 12 , namely as difference from the direct estimates having a common arm. The corresponding 95% credibility intervals (CrI) were obtained by the normal approximation.
A credible interval is a probability interval or rather a probabilistic region around a posterior moment, and its use is similar to a frequentist confidence interval. We carried out the Bayesian networkmeta-analyses with both the fixed or random effect model and we selected the better model in terms of fit and parsimony, calculating the posterior mean of residual deviance (D res ) and the Deviance Information Criterion (DIC) statistics.
The consistency assumption, that means no discrepancy between direct and indirect comparisons, was verified in the Bayesian network analysis, by evaluating a probability .0.5 of the difference of both the consistency and inconsistency residual deviance. Furthermore, we compared the results obtained fitting the consistency model, estimating only the effects between each study treatment (levosimendan, enoximone, milrinone, dobutamine) and the reference one (placebo) and deriving the indirect treatment effects by consistency equation, and the inconsistency model, which provides the prior distribution for all possible combinations of treatments. 54 55 To explore the relation between log-risk of mortality and the length of study follow-up (in days), we performed Bayesian meta-regression analyses. Sensitivity Bayesian analysis was Due to zero-cell events in each comparisons that included enoximone treatment (mortality data were reported but no patient died in the studies including enoximone), we carried out a sub Bayesian network meta-analysis combining enoximone and milrinone groups. Other methodological details for the Statistical analyses and for the conduction of the Bayesian network meta-analyses are reported in the Supplementary Appendix S2.
Finally, we calculated the posterior distribution of the probability to be the first, the second, the third and the worst treatment and we show the correspondent cumulative rank curves.
The statistical analysis was performed by STATA (release 11, College Station, TX) and winBUGS (release 1.4, freeware available by BUGS project). Figure 1 shows the flowchart for the selection of randomised trials. The references of major exclusions are available after contacting the authors. Forty-six randomised clinical trials 9 -53 were included in the final analysis ( Table 1 ). The study characteristics of included trials are detailed in Supplementary Appendix S3.
Results

Description of included trials
Briefly, the 46 trials randomised 2647 patients, including 1044 (39%) patients receiving placebo, 893 (34%) receiving levosimendan, 390 (15%) receiving milrinone, 273 (10%) receiving dobutamine, and 47 (1.8%) receiving enoximone. Nineteen (41%) of the randomised controlled trials were at low risk of bias while 52 and 7% were at moderate and high risk of bias respectively, lacking important details on the method used to generate random sequence, on allocation or on the intention to treat analyses (Supplementary Table S1 ).The lack of blinding was the main bias and the main reason of low quality for the included trials.
Quantitative data synthesis
The network configuration in Figure 2 connects treatments that have been directly compared in one or more RCTs and shows that almost half of the studies compared levosimendan vs placebo.
We also performed eight simple pairwise meta-analyses comparing each agent against each other agent (Supplementary Figures S1 and S2 ). Only the use of levosimendan was associated with a reduction in mortality. The reduction in mortality was present when levosimendan was compared with placebo (35/ Figure S3) .The superiority of levosimendan vs placebo was confirmed when sequentially removing each study while the superiority of levosimendan vs dobutamine was lost when removing one large trial. 39 The Bayesian network meta-analysis (Table 2) found that only the use of levosimendan was associated with a decrease in mortality. The survival benefit was limited to the comparison with placebo (posterior mean of OR¼0.48, 95% CrI 0.28 to 0.80) with the model having a good fit (D res ¼155.8 and DIC¼183.7). The validity of consistency analysis were confirmed by a low probability in favour of inconsistency model (probability¼0.01). The similarity between the effect estimated by both consistency and inconsistency model, was shown in the Supplementary Figure S4 .
Furthermore, the Bayesian meta-regressions of average follow-up against log-risk of mortality showed no significant time-related effects on mortality (regression coefficient¼0.005 CrI 20.001 to 0.011, days). Table 3 show the results of sensitivity analyses: the beneficial effect of levosimendan vs placebo was confirmed changing the prior distribution, with studies not supported by a drug company and removing the largest study, 40 however, analysing the 19 low risk of bias trials, this superiority was lost. We also performed a second analysis combining the enoximone and milrinone groups (D res ¼155.9 and DIC¼183.7) to overcome the zero-cell count problem ( Table 2 ) and confirmed that levosimendan was better than placebo. Table 4 reports the posterior distribution of the probability for each inodilator to be the best and the worst drug, showing that levosimendan is the best agent to improve survival after cardiac surgery. Figure 3 shows the cumulative rank curves of the probability to be the first, the second, the third and the worst treatment, confirming that levosimendan is the best treatment.
Discussion
The main finding of this study is that only treatment with levosimendan is associated with mortality reduction in cardiac surgery. This Bayesian network meta-analysis suggested that levosimendan is associated with the lowest risk of mortality among the comparators included in the study: the inodilators PDE-3 inhibitors enoximone and milrinone, the classic dobutamine and placebo. The superiority of levosimendan vs placebo was confirmed both in the simple pairwise and in Bayesian network meta-analysis while the superiority of levosimendan vs dobutamine was present in the pairwise but not confirmed in the network meta-analysis. These findings should be treated with caution because the statistical significance was lost when sensitivity analyses including only low risk of bias study were performed and because no multicentre randomised trial to confirm these findings exists. Notably, the Bayesian metaanalysis failed to rank inodilators: with the notable exception of levosimendan, the other studied drugs are either similar one each other or not properly studied so far not allowing to reach a statistically significant difference among them in mortality, even using indirect comparisons.
The real effects of inodilators on mortality in cardiac surgery have been the 'white whale' for many years. Our study summarises the data on mortality from all randomised trials on inodilators in a single picture, including direct and indirect comparisons. Levosimendan was superior to placebo and, overall, it was the best agent to reduce perioperative mortality. Effect of inodilatory agents on mortality BJA A meta-regression, performed to detect if differences in the length of follow up weighted on results, showed no significant effect of time on mortality. These findings confirm previous evidence from meta-analyses of randomised controlled studies that showed a beneficial effect of levosimendan on survival in the populations of cardiac surgery 56 and critically ill patients. 57 However, previous analyses lacked the indirect comparisons and the ranking among different comparators and did not focus on inodilators, therefore their results were less robust and useful than the present results. Furthermore, they either included any settings of critically ill patients 57 or, when focusing on cardiac surgery, were not as updated as the present analysis. 56 We performed a Bayesian network meta-analysis to answer an important clinical question: 'what is the effect of levosimendan, enoximone, milrinone and dobutamine on survival in adult patients undergoing cardiac surgery?' The Bayesian network meta-analysis approach was deemed to be the most appropriate because it can integrate direct and indirect effect estimates and can compare drugs that did not undergo sufficient head-to-head comparison in the original clinical trials. In this way, it was possible to identify levosimendan as the best treatment according to published randomised evidence. We focused on adult patients undergoing cardiac surgery and receiving inodilator because this is a widespread and relatively standardised setting and because inodilators are the most frequently used and studied agents worldwide in this setting. While levosimendan has been demonstrated to be the safest among inodilators, its main drawback resides in its high costs. Treatment with levosimendan might increase patient cost per recovery. 58 However, higher drug expenses are balanced by its beneficial effect on the length of hospital stay and on complications. 59 While this is true for developed countries, treatment with levosimendan seems to be nonetheless expensive and thus not always available in every country for economic reasons. The probability to be the best or the worse inodilator, reported in Table 4 , should not be underestimated, as it enables physicians worldwide to choose the best drug for their patient, basing their decision on their local resources. Nonetheless, it should be remembered that our findings should be taken cautiously because the statistical significance was lost when sensitivity analyses including only low risk of bias study were Table 4 Posterior distribution of the probability to be the best and the worst for each inodilators drug, derived by Bayesian hierarchical model with Markov Chain Monte Carlo algorithm
Drugs
Overall Bayesian network meta-analysis Combining enoximone and milrinone groups Probability to be the best Probability to be the worst Probability to be the best Probability to be the worst Effect of inodilatory agents on mortality performed. To confirm the findings of this study, a large multicentre factorial randomised controlled trial comparing levosimendan vs PDE-3 inhibitors, dobutamine and placebo should be conducted. Alternatively, we should wait for the results of the two large multicentre randomised trials should comparing levosimendan vs placebo on top of the best available treatment that are running so far in Europe (NCT00994825) and in the United States (NCT02025621).
Limitations
The major weakness of indirect meta-analysis is that confounding can be a major bias. That is, the risk status of one study cohort may be markedly different of another. Furthermore, several RCTs included in our meta-analysis were of suboptimal quality. Nonetheless, our conclusions are based on 41% of studies of high quality and all the sub-analyses performed confirmed that levosimendan treatment improves survival when compared with placebo. Notably, thirty-six further studies were excluded because they lacked data on mortality outcome and authors did not answer to our request to provide these data. This limited the power of the analysis and the precision of results. At the same time, we focused on mortality, the most clinically relevant outcome and the one less subject to interpretation, we used several databases to identify the pertinent studies and we focused on randomised trials only. The comparisons included different numbers of trials depending on study drugs, while trials differed by number of included patients, surgical settings and mortality risk of their populations. Some studies only included patients with low cardiac output syndrome after cardiac surgery, without other specifications. A large part of included studies did not report on funding, thus making more difficult to draw conclusion on the possible influence of drug companies on the results of the original papers. Data from trials on enoximone had zero-cell counts and we had to repeat a second analysis combining PDE-3 inhibitors. Dose and length of drugs administration were heterogeneous and not reported in our tables, nonetheless they corresponded to local routine practice. At the same time, since inotropic drugs are often considered to be lifesaving in cardiac surgery most trials had placebo on top of standard treatment as comparator and not placebo only. Bayesian network meta-analysis incorporates both direct and indirect comparisons between treatments. However indirect evidence is susceptible to confounding, 6 and thus should be interpreted with caution since it does not always agree with the corresponding direct estimates. 7 Since the indirect estimate derives results from the direct effects of two treatments vs a third common comparator, it can confound the overall results because it not always agrees with the corresponding direct estimates. This bias results in a greater pooled estimate variability. 7 Like heterogeneity in traditional random-effects models of meta-analysis, the comparison between the consistency and the inconsistency model is used to quantify variation among estimates and is incorporated into the estimate of the confidence interval. 60 The discrepancy between consistency and inconsistency estimates could be used to evaluate the convergence between direct and indirect comparisons. 61 Although the consistency hypothesis was not rejected in this Bayesian network meta-analyses, additional methodological and empirical work needs to be done to evaluate the direct and indirect comparisons across a number of types of interventions. Bayesian network metaanalyses assume that patients enrolled in the individual studies could have been sampled from the same theoretical population, and that similar comparators between different trials have a consistent risk-benefit ratio. Furthermore, traditional limitations of meta-analyses 62 due to variations in the treatment regimens, in populations or major subgroups within trials, and in the conduction of the trials also apply to this Bayesian network meta-analysis. After reading our study, physicians might consider choosing levosimendan when needing to use an inodilator in cardiac surgery. This drug is the most frequently studied and the only one with a documented effect on mortality reduction in this setting when compared with placebo. At the same time, the other inodilators have never been properly compared with placebo or in head to head comparisons to other inodilators. In particular, enoximone was compared only once against placebo and once against dobutamine in spite of being extensively used in several countries. Moreover, even using Bayesian network techniques it is not possible to reach definite conclusions on their effects on mortality and on their ranking when compared with other inodilators. Since most evidence comes from small single centre studies and levosimendan is still an expensive drug, there is still need to wait for the results of large multicentre RCTs that will have to confirm the benefit of levosimendan on survival and on clinically relevant outcomes in cardiac surgery.
Conclusions
This manuscript is the most updated and methodologically strongest meta-analysis on the effect of inodilators on mortality in cardiac surgery. Using Bayesian network meta-analyses techniques, we attempted ranking among different inodilators that have never properly been compared one each other, and identified levosimendan to be the best inodilator to improve survival in adult cardiac surgery. Since meta-analyses are hypothesis generating and our findings were not confirmed when limiting the analysis to low risk of bias studies, these results should be confirmed by large multicentre RCTs. 
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